drugset / Trial / NCT02934828
Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators research aim to explores the optimal comprehensive treatment for TNBC and her2 positive breast cancer by comparing the efficacy of neoadjuvant with that of adjuvant treatment in improvement of RFS.
Timeline
- Start
- 2014-10
- Primary completion
- 2017-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 4 unknown | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |